No AstraZeneca Cash Takeover; BTG Offers Protherics Stock Deal Instead
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger valued at $396 million-plus, but widely speculated sepsis partner not the one.
You may also be interested in...
Genzyme/Bayer Hope To Fly With Single Campath Phase III Trial In MS
Firms will not wait to complete second Phase III study before filing for MS indication, Genzyme says.
AstraZeneca Licenses Protherics Sepsis Treatment
AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf